Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
FN-1501 inhibits FLT3, CDK2, CDK4, and CDK6, resulting in decreased downstream signaling and potentially leading to reduced tumor cell proliferation and tumor growth (PMID: 29357250).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|FN-1501||FN1501|FN 1501||CDK2 Inhibitor 26 CDK4 Inhibitor 16 CDK6 Inhibitor 6 FLT3 Inhibitor 62||FN-1501 inhibits FLT3, CDK2, CDK4, and CDK6, resulting in decreased downstream signaling and potentially leading to reduced tumor cell proliferation and tumor growth (PMID: 29357250).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 exon 14 ins||leukemia||sensitive||FN-1501||Preclinical - Cell line xenograft||Actionable||In a preclinical study, treatment with FN-1501 reduced phoshorylation of FLT3 and downstream STAT5, ERK, and AKT, induced apoptosis and cell-cycle arrest, and decreased proliferation in a human leukemia cell line harboring a FLT3-ITD mutation in culture, and induced tumor regression in xenograft models (PMID: 29357250).||29357250|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03690154||Phase I||FN-1501||Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of FN-1501 Monotherapy in Patients With Advanced Solid Tumors||Terminated||USA | AUS||0|